Ruiz-Tovar Jaime, Martínez-Molina Enrique, Morales Vicente, Sanjuanbenito Alfonso
Departamento de Cirugía General y del Aparato Digestivo, Hospital Universitario Ramón y Cajal, Madrid, España.
Cir Esp. 2009 Jun;85(6):354-9. doi: 10.1016/j.ciresp.2008.12.007. Epub 2009 Apr 2.
Primary small bowel adenocarcinoma is an uncommon tumour, with non-specific symptoms that cause a delay in the diagnosis and consequently a worse outcome for the patient. We analyse our experience in the management of this disease.
We performed a retrospective study of our experience with 17 patients diagnosed with primary small bowel adenocarcinoma, excluding all the cases suggesting secondary involvement of the small bowel from an adenocarcinoma in other locations.
We analysed 9 females (53%) and 8 males (47%) with a mean age of 61.8 years. Tumour location was duodenum (8 cases), jejunum (5) and ileum (4). Those with duodenal tumours underwent 4 pancreaticoduodenectomies, 3 gastroenterostomies and 1 diagnostic biopsy; 6 bowel resections with lymphadenectomy, 2 en-bloc resections and 1 by-pass were performed on those with jejuno-ileal tumours. There were complications in 3 patients (18%). General survival was 18 months; in duodenal and jejunal tumours it was 15 months vs. 58 in ileal ones (p = 0.048). Survival was 48 months in the absence of lymph node metastases vs. 11 in those with (p = 0.067). In those tumours infiltrating the retroperitoneum, survival was 15 months compared to 23 when not affected (p = 0.09).
Curative treatment consists of small bowel resection. Retroperitoneal infiltration was a non-resectability criterion in our series. Ileal location is associated with a better outcome. Advanced stages, lymph node metastases, non-resected cases and retroperitoneal infiltration tended to be associated with a poor prognosis in our group.
原发性小肠腺癌是一种罕见肿瘤,其症状不具特异性,导致诊断延迟,进而使患者预后更差。我们分析了我们在该疾病治疗方面的经验。
我们对17例诊断为原发性小肠腺癌的患者的经验进行了回顾性研究,排除了所有提示小肠受其他部位腺癌继发性累及的病例。
我们分析了9名女性(53%)和8名男性(47%),平均年龄61.8岁。肿瘤位于十二指肠(8例)、空肠(5例)和回肠(4例)。十二指肠肿瘤患者接受了4例胰十二指肠切除术、3例胃肠吻合术和1例诊断性活检;空肠-回肠肿瘤患者进行了6例肠切除术及淋巴结清扫、2例整块切除术和1例旁路手术。3例患者(18%)出现并发症。总体生存期为18个月;十二指肠和空肠肿瘤患者的生存期为15个月,而回肠肿瘤患者为58个月(p = 0.048)。无淋巴结转移患者的生存期为48个月,有淋巴结转移患者为11个月(p = 0.067)。在那些浸润腹膜后的肿瘤中,生存期为15个月,未受影响者为23个月(p = 0.09)。
根治性治疗包括小肠切除术。在我们的系列研究中,腹膜后浸润是不可切除的标准。回肠部位与较好的预后相关。在我们的研究组中,晚期、淋巴结转移、未切除病例和腹膜后浸润往往与预后不良相关。